Clonal Tracking of Autoaggressive T Cells in Polymyositis by Combining Laser Microdissection, Single-cell PCR, and CDR3-spectratype Analysis
Overview
Authors
Affiliations
Clonal expansions of CD8+ T cells have been identified in muscle and blood of polymyositis patients by PCR techniques, including T cell receptor (TCR) complementarity-determining region (CDR)3 length analysis (spectratyping). To examine a possible pathogenic role of these clonally expanded T cells, we combined CDR3 spectratyping with laser microdissection and single-cell PCR of individual myocytotoxic T cells that contact, invade, and destroy a skeletal muscle fiber. First, we screened cDNA from muscle biopsy specimens by CDR3 spectratyping for expanded TCR beta chain variable region (BV) sequences. To pinpoint the corresponding T cells in tissue, we stained cryostat sections with appropriate anti-TCR BV mAbs, isolated single BV+ T cells that directly contacted or invaded a muscle fiber by laser-assisted microdissection, and amplified their TCR BV chain sequences from rearranged genomic DNA. In this way, we could relate the oligoclonal peaks identified by CDR3-spectratype screening to morphologically characterized microdissected T cells. In one patient, a large fraction of the microdissected T cells carried a common TCR-BV amino acid CDR3 motif and conservative nucleotide exchanges in the CDR3 region, suggesting an antigen-driven response. In several cases, we tracked these T cell clones for several years in CD8+ (but not CD4+) blood lymphocytes and in two patients also in consecutive muscle biopsy specimens. During immunosuppressive therapy, oligoclonal CDR3-spectratype patterns tended to revert to more polyclonal Gaussian distribution-like patterns. Our findings demonstrate that CDR3 spectratyping and single-cell analysis can be combined to identify and track autoaggressive T cell clones in blood and target tissue. This approach should be applicable to other inflammatory and autoimmune disorders.
Experimental myositis: an optimised version of C-protein-induced myositis.
Giannini M, Rovito D, Oulad-Abdelghani M, Messaddeq N, Debrut L, Quiring G RMD Open. 2025; 11(1).
PMID: 40044571 PMC: 11883622. DOI: 10.1136/rmdopen-2024-004558.
Guglielmi V, Cheli M, Tonin P, Vattemi G Int J Mol Sci. 2024; 25(5).
PMID: 38473988 PMC: 10932328. DOI: 10.3390/ijms25052742.
Reay D, Tabib T, Wang Y, Oriss T, Young N, Lafyatis R Front Immunol. 2023; 14:1238221.
PMID: 37809058 PMC: 10556668. DOI: 10.3389/fimmu.2023.1238221.
Dalakas M Acta Myol. 2021; 39(4):289-301.
PMID: 33458584 PMC: 7783437. DOI: 10.36185/2532-1900-032.
Polymyositis and dermatomyositis - challenges in diagnosis and management.
Yang S, Chang C, Lian Z J Transl Autoimmun. 2020; 2:100018.
PMID: 32743506 PMC: 7388349. DOI: 10.1016/j.jtauto.2019.100018.